Welcome to our dedicated page for Novo Nordisk A/S news (Ticker: NVO), a resource for investors and traders seeking the latest updates and insights on Novo Nordisk A/S stock.
Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk (NVO) and UNICEF will expand their global partnership with a four-year childhood overweight and obesity prevention programme from 2027 to 2030, aiming to support a healthier start for more than 80 million children in seven countries.
Novo Nordisk will commit USD 18 million from 2026 to 2030, with funding beginning in 2026 to support programme inception and preparation. The programme will focus on policy and community action in Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya, where most affected children live in low- and middle-income settings.
Interventions include growth monitoring, nutrition and physical activity counselling, peer and family support, community- and facility-based prevention, youth advocacy, basic mental health screening and support, and legislation to promote healthier diets. Delivery will be country-led and anchored in UNICEF’s Centres of Excellence model.
Novo Nordisk (NVO) reports continued execution of its 2026 share repurchase programme, detailing B share buybacks completed through 18 September 2026.
The current programme, running from 6 May 2026 to 1 February 2027, allows repurchases of up to DKK 11,200,000,010.45 and forms part of a broader 12‑month buyback of up to DKK 15 billion starting 4 February 2026. From 14–18 September, the company repurchased a total of 1,090,000 B shares, bringing accumulated purchases under this programme to 19,415,000 B shares for DKK 5,829,922,946. As of 18 September, total repurchases since 4 February amount to 34,174,179 B shares for DKK 9,629,922,935, and Novo Nordisk now holds 48,214,876 B shares (1.1% of share capital) as treasury shares out of total A and B shares of 4,465,000,000.
Novo Nordisk (NVO) reported phase 3 topline results showing once-weekly CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes in the REIMAGINE 5 trial.
CagriSema also delivered a non-inferior HbA1c reduction of 1.71% versus 1.67% for tirzepatide. In the REDEFINE 9 obesity trial, CagriSema 1.0 mg/1.0 mg produced 21.0% weight loss versus 2.0% with placebo at week 68, meeting the primary superiority endpoint and improving prespecified measures such as systolic blood pressure, waist-to-height ratio and fasting lipid profile. Across both trials, CagriSema was well tolerated overall, with a safety profile consistent with earlier studies. Novo Nordisk has filed a CagriSema New Drug Application for weight management with a US FDA decision expected in Q4 2026.
Novo Nordisk (NVO) is hosting a 2026 Capital Markets Day in London to update investors on its corporate strategy and strategic ambitions for 2030.
Management presentations cover corporate and R&D strategy, therapy-area positioning, commercial strategy in the US and internationally, global manufacturing and supply, and financials. Strategic ambitions include launching more than five multi-blockbuster products by 2030 and targeting over 150 billion DKK in risk-adjusted pipeline sales in 2035. The company aims for at least five Phase 3 programmes in obesity and diabetes and at least five in other therapy areas, a 2026–2030 revenue CAGR in line with selected industry peers, the capacity to serve 10 times more people with obesity on oral GLP-1, service of more than 60 million patients globally by 2030, broadly stable operating margins and an attractive dividend per share.
Novo Nordisk (NVO) received a positive CHMP opinion recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature (ISS) and persistent growth disturbance.
If approved, Sogroya would be the first and only growth hormone treatment authorised for ISS in the EU, adding to earlier CHMP recommendations for children born small for gestational age and with Noonan Syndrome. In the phase 3 REAL8 trial, once-weekly Sogroya was non-inferior to once-daily growth hormone for mean annualised height velocity at Week 52 in children with ISS, SGA and NS. The opinion now goes to the European Commission, with a marketing authorisation decision covering all three indications expected later in 2026. Sogroya is already approved in the EU for growth hormone deficiency in adults and in children aged 3 years and older.
Novo Nordisk (NVO) received a positive CHMP opinion recommending EU marketing authorisation for FREHEMGO (denecimig) to treat haemophilia A with or without inhibitors in adults and children.
FREHEMGO is a factor VIIIa mimetic bispecific antibody for routine prophylaxis, offering once‑monthly, once‑every‑two‑weeks and once‑weekly dosing in a single‑use pre‑filled pen. The recommendation is based on the phase 3 FRONTIER programme, where denecimig achieved consistently low mean annualised bleeding rates, generally below 1, with many participants having zero treated bleeds, and no new safety signals on switching from emicizumab. Novo expects initial launches in select European countries in Q4 2026 and broader EU rollout from early 2027, pending final EMA approval.
Novo Nordisk (NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude models, including Claude Science, to Novo’s R&D and software engineering. The partnership focuses on using AI to tackle specific drug discovery and biological reasoning challenges, speed up development of new medicines, and enhance AI-driven software development under defined data governance and human oversight frameworks.
Novo Nordisk (NVO) will present new real-world and clinical data from its cardiometabolic portfolio and pipeline at the 62nd EASD Annual Meeting in Milan, Italy, from 28 September to 2 October 2026.
The company will share 44 abstracts covering semaglutide, CagriSema, zenagamtide and other candidates across obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease. Highlights include real-world OCTANE study data on Wegovy® pill in adults with overweight or obesity, semaglutide analyses on liver fat and cardio‑renal outcomes, and COMPETE SWITCH CV data comparing major cardiovascular events when escalating to Ozempic® 2.0 mg versus switching to tirzepatide. Additional presentations focus on next‑generation amylin‑based treatments such as CagriSema and zenagamtide, including effects on appetite regulation, food cue brain responses, body composition and bone remodelling.
Novo Nordisk (NVO) reports progress on its B share repurchase programme for the period 7–11 September 2026.
The buyback is part of an overall programme of up to DKK 15 billion to be executed over 12 months beginning 4 February 2026. Under the sub-programme initiated on 6 May 2026, Novo Nordisk may repurchase B shares up to DKK 11,200,000,010.45 between 6 May 2026 and 1 February 2027. From 7–11 September 2026, the company bought 1,050,000 B shares at average prices between DKK 278.62 and DKK 297.98, for DKK 304,412,195 in total. Cumulatively under this sub-programme, 18,325,000 B shares have been repurchased for DKK 5,526,186,488. Since 4 February 2026, 33,084,179 B shares have been bought back for DKK 9,326,186,478, and Novo Nordisk now holds 47,124,876 B shares as treasury shares, equal to 1.1% of its 4,465,000,000 total shares.
Novo (NVO) has launched a corporate rebrand built around the tagline “Lasting Health Starts Now” and will use the single “Novo” name in day-to-day communication, while Novo Nordisk A/S remains the legal name.
The rebrand introduces an updated visual identity featuring the heritage Apis bull logo in a more contemporary form and aims to create a more recognisable and relevant presence across medicines, partnerships and marketing. In parallel, Novo has introduced “The Novo Way”, a new cultural framework based on four principles: Customer Obsession, Competitiveness, Clarity, and Care & Integrity, intended to guide behaviours and ways of working in a faster, more consumer‑driven healthcare market.